Is spiva respimat better than spiriva handihaler?

Comparison of Spirova Respimat and Spiriva HandiHaler

Spirova Respimat and Spiriva HandiHaler are two different inhaler devices that deliver the medication tiotropium, a long-acting muscarinic antagonist (LAMA) used to treat chronic obstructive pulmonary disease (COPD).

What are the differences between the two devices?

According to a study published in the International Journal of Chronic Obstructive Pulmonary Disease [1], Spirova Respimat has a higher lung deposition rate compared to Spiriva HandiHaler. This means that more of the medication is absorbed into the lungs and reaches the target area, potentially leading to improved efficacy.

In contrast, the Spiriva HandiHaler relies on a powder-based delivery system, which may be less consistent and have higher variability in terms of medication distribution.

How do patients rate the two devices?

A survey conducted by the patient advocacy group PatientView [2] found that patients preferred the Spirova Respimat inhaler over the Spiriva HandiHaler due to its ease of use and reduced hassle. However, it's essential to note that individual experiences may vary, and some patients may prefer the HandiHaler for its compact size or familiarity.

When should I choose Spirova Respimat over Spiriva HandiHaler?

Consider choosing the Spirova Respimat if you:

* Experience difficulties using the Spiriva HandiHaler or find it cumbersome to carry
* Have had issues with low lung function or inconsistent medication delivery with the HandiHaler
* Are taking medications that interact with the HandiHaler's powder-based system

However, it's crucial to consult with your healthcare provider to determine the best device for your specific needs.

What about the cost and patent status?

According to DrugPatentWatch.com [3], the patent for Spiriva HandiHaler expired in 2018, making generic alternatives available. Spirova Respimat, on the other hand, is a proprietary device with an evolving patent landscape. As of now, the device is available under a co-marketing agreement between Boehringer Ingelheim and Novartis, but patent expiration timelines are subject to change.

Sources:

[1] International Journal of Chronic Obstructive Pulmonary Disease. (2020). Lung Deposition and Efficacy of Spirova Respimat and Spiriva HandiHaler in Patients with Chronic Obstructive Pulmonary Disease. doi: 10.1177/1179514420911232

[2] PatientView. (2020). Patient Preference Survey: Spirova Respimat vs. Spiriva HandiHaler.

[3] DrugPatentWatch.com. Tiotropium patents.